Excisional Vacuum-Assisted Breast Biopsy

Status Recruiting

Clinical Trial Summary

The goal of this prospective cohort study is to evaluate the possibility of vacuum-assisted excisional biopsy (VAE) to completely remove the pathology in case of small lesions for Atypical Ductal Hyperplasia (ADH) and low-intermediate grade Ductal Carcinoma in Situ (DCIS).

Clinical Trial Description

Surgery is the current standard of care of breast lesions like the Ductal Carcinoma In Situ (DCIS) and the Atypical Ductal Hyperplasia (ADH). However, the survival benefit of surgical resection in patients with such lesions appears to be low, especially for ADH and low-grade DCIS where comorbidity of surgery and prior depression have been reported as important factors related to worse quality of life in these women. Patients with suspicious breast lesions (BIRADS>3) who are candidates for vacuum assisted breast biopsy will be prospectively select and enroll if the radiological lesion diameter is less than 15 mm. The investigators will select those patients in whom after an initial sequence of sampling (12 cores), and will check the complete macroscopic removal of the lesion (with radiograms of the biopsied part of the breast). Those patients (complete macroscopic removal, with real-time verification during the procedure) will be randomized into two groups. A first group of patients will finish the biopsy procedure after the first collection sequence (12 cores, 3 grams of tissue taken and complete macroscopic removal). A second group of patients (randomized subdivision) will undergo a second sequence of biopsy samples (other 4 cores and 1 gram of tissue taken) in the same session: the material collected will be sent separately to the pathologist. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05932758
Study type	Interventional
Source	European Institute of Oncology
Contact	Luca Nicosia, MD
Phone	+390294372449
Email	luca.nicosia@ieo.it
Status	Recruiting
Phase	N/A
Start date	January 17, 2023
Completion date	July 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02889458` - Hong Kong Breast Cancer Study
Completed	`NCT00757302` - Intraoperative Gamma Camera for Breast Cancer Surgery	Phase 3
Recruiting	`NCT03216421` - Intraoperative Radiation Therapy (IORT) in DCIS	N/A
Completed	`NCT03775213` - Acceptability of Active Monitoring (AM) as a Treatment Option for Ductal Carcinoma in Situ (DCIS)	N/A
Active, not recruiting	`NCT00605982` - Breast MRI as a Preoperative Tool for DCIS	N/A
Enrolling by invitation	`NCT04365114` - Patient Outcomes From Second Film-readers and Test Threshold Relaxation in Breast Screening
Completed	`NCT04248179` - The Ultrasound-guided Multiple-injection Costotransverse Block for Mastectomy and Primary Reconstructive Surgery.	Phase 4
Withdrawn	`NCT05032079` - Subzero and Scorpion Trial	N/A
Recruiting	`NCT05218044` - Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ	N/A
Active, not recruiting	`NCT01644669` - Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®	N/A
Recruiting	`NCT06133647` - Demographics, Characteristics and Outcomes of Male Breast Cancer Patients at Methodist Health System
Completed	`NCT01815476` - The Prone Breast Radiation Therapy Trial	N/A
Not yet recruiting	`NCT06033092` - Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion	Phase 2
Terminated	`NCT02137252` - Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer	Phase 2
Terminated	`NCT01060345` - A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ	Phase 2
Recruiting	`NCT00669747` - Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)	Phase 2
Completed	`NCT00742222` - Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer	Phase 4
Active, not recruiting	`NCT02909426` - The Mammography and Ultrasonography STudy for Breast Cancer Screening Effectiveness
Recruiting	`NCT02928978` - Ruxolitinib for Premalignant Breast Disease	Phase 2
Completed	`NCT03375892` - The Use of Deep Inspiration Breath Hold and Prone Irradiation to Decrease Cardiac Radiation Exposure	N/A